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Plasma chromogranin A marks emesis and serotonin release associated
with dacarbazine and nitrogen mustard but not with cyclophosphamide-
based chemotherapies
LX Cubeddul, DT O'Connor2, I Hoffmann' and RJ Parmer2
'Department ofPharmacology, School ofPharmacy, Central University of Venezuela, Caracas, Venezuela; 'Department of
Medicine, University ofCalifornia, and Veterans Administration Medical Center, San Diego, California, USA.
Summary Chromogranin A (CgA) is present in high concentrations in enterochromaffin cells, where it is
co-localised with serotonin in the storage granules. Plasma CgA has been reported to mark emesis and
serotonin release associated with cisplatin treatment. However, it is not known whether plasma CgA could be
an indicator of emesis and of serotonin release in patients receiving non-cisplatin chemotherapies. Therefore,
in this study we evaluated, in cancer patients, the temporal relationships between the increases in plasma CgA
and urinary 5-hydroxyindoleacetic acid (5-HIAA) and the development of vomiting following dacarbazine,
nitrogen mustard and cyclophosphamide treatments. Metoclopramide was used as antiemetic. With dacar-
bazine, nitrogen mustard and cyclophosphamide the median time to the onset of emesis was 2.3, 2.8 and 5.3 h
and the duration of intense emesis was 3, 2 and 6 h respectively. Plasma CgA and urinary 5-HIAA increased
after dacarbazine- and nitrogen mustard-based chemotherapies, with maximal increases between 4 and 6 h
after initiation of drug infusion. The time course for the increases in plasma CgA paralleled that of urinary
5-HIAA and the period of intense emesis. A highly significant (P = 0.0009) positive correlation (r = 0.68) was
found between the increases in plasma CgA and in urinary 5-HIAA. Cyclophosphamide treatment was not
associated with increases in plasma CgA and in urinary 5-HIAA, despite inducing emesis; this indicates that
the increases in CgA and 5-HIAA after dacarbazine and nitrogen mustard are not due to the act of vomiting
per se. In summary, plasma CgA is a marker of serotonin release (most likely from enterochromaffin cells)
after dacarbazine and nitrogen mustard-based chemotherapies, exocytosis being the most likely mechanism for
the release of serotonin. Serotonin released from enterochromaffin cells seems to trigger the emetic response to
dacarbazine and nitrogen mustard; however, cyclophosphamide may release serotonin from a different pool
(enteric serotonin neurons and/or CNS serotonin?).
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Chromogranin A (CgA) is a protein located in neurotrans-
mitter- and hormone-containing secretory vesicles (O'Connor
et al., 1984; Winkler and Fischer-Colbrie, 1992). This protein
is encountered in very high concentrations in the gastrointes-
tinal tract (O'Connor et al., 1983; Facer et al., 1985; Varndell
et al., 1985), in particular in enterochromaffin cells (Cetin
and Grube, 1991; Bargsten and Grube, 1992), where it is
stored along with serotonin in the core of secretory vesicles
(Bargsten and Grube, 1992). CgA is present in plasma; how-
ever, little is known about its origin and significance (O'Con-
nor et al., 1983, 1984). In a recent study, we demonstrated
large increases in plasma CgA in cancer patients receiving
treatment with cisplatin (Cubeddu et al., 1994a). The inc-
reases in plasma CgA associated with cisplatin
chemotherapy, correlated with the development of emesis
and with increases in the urinary excretion of 5-
hydroxyindoleacetic acid (5-HIAA), the main metabolite of
serotonin in humans. It was thus proposed that CgA in
plasma could be a marker of cisplatin-induced serotonin
release from gastrointestinal enterochromaffin cells, and a
convenient and valuable tool to study the mechanisms of
emesis associated with chemotherapeutic drugs (Cubeddu et
al., 1994a).
The present work was conducted to investigate further, in
cancer patients, the value of plasma CgA as a possible
marker of emesis and of the release of gastrointestinal
serotonin. Since CgA co-release with amines and neurotrans-
mitters is the basis of the concept of exocytosis (O'Connor
and Bernstein, 1984; Takiyyuddin et al., 1990), we also inves-
tigated the mechanism of serotonin release induced by other
commonly employed chemotherapeutic drugs. In this study
we measured the pattern ofemesis and the changes in plasma
CgA concentrations and in serotonin metabolism induced by
chemotherapeutic drugs other than cisplatin. Chemotherapy
regimens known to produce emesis of high to moderate
severity were employed. Patients scheduled to receive either
dacarbazine, nitrogen mustard (highly emetogenic
treatments) or cyclophosphamide-based chemotherapies
(moderately emetogenic treatment) were studied. Since the
urinary excretion of 5-HIAA reflects the release of gast-
rointestinal serotonin (Bertaccini, 1960; Bertaccini and
Chieppa, 1960), in this work, simultaneous measurements of
plasma CgA and urinary 5-HIAA were performed to deter-
mine whether the increases in plasma CgA were related to
the release of serotonin. In addition, by studying the pattern
of emesis after each of the three chemotherapeutic drug
regimens employed it was possible to explore the temporal
relationships between the release of serotonin (plasma CgA
and urinary 5-HIAA) and the development of emesis.
Methods
Patients
A total of 20 patients with histologically confirmed cancer,
18 years of age or older, who had not received previous
chemotherapy, and had a Karnofsky performance score of at
least 60% were enrolled in the study. Patients were excluded
from the study if they had abnormal liver or renal function
tests, or had any nausea and vomiting within 24 h of the
study period. Patients who received abdominal or pelvic
radiation therapy within 48 h before or during the day of the
study were also excluded. Written informed consent was
obtained from all patients. The study protocol was evaluated
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and accepted by the Institutional Review Board at par-
ticipating institutions, and conducted at the medical oncology
divisions of the Luis Razetti and Padre Machado Hospitals
of the city of Caracas.
Chemotherapy
Dacarbazine (193 ± 34 mg m-2; range 188-286 mg m-2), nit-
rogen mustard (4.9 + 0.4mgm2; range: 1.1-6Mmgm2) or
cyclophosphamide (613
± 99 mg m-2; range: 500-1000 mg
m-2) were given dissolved in 500 ml of 5% dextrose in 0.45%
sodium chloride administered as a 60 min intravenous
infusion. Hydration with 5% dextrose in 0.45% sodium
chloride was continued at a rate of 150-200 ml h' for the
next 12 h. The associated chemotherapeutic drugs were
administered after the primary agent (Table I).
Antiemetics
Patients received two intravenous doses of 2 mg kg- each of
metoclopramide. The first dose was given 30 min before the
initiation of the chemotherapy and the second dose 2 h after
the administration of the main chemotherapeutic drug
(dacarbazine, nitrogen mustard or cyclophosphamide). In the
event of persisting nausea and/or vomiting, one or two addi-
tional doses of metoclopramide were administered.
Patients were continuously monitored for nausea and
emesis for 10 h after administration of the main agent; subse-
quently, the emetic episodes were recorded by the patient in a
diary. The number and the time of each emetic episode were
registered. The total number of emetic episodes consisted of
the number of vomiting episodes plus the number ofepisodes
of dry retching.
Measurements ofplasma CgA
Blood samples were drawn from an antecubital vein after a
minimum of 60 min of recumbency. Samples were obtained
at time zero (baseline) and at 1, 3, 5, 7 and 24 h after the
main chemotherapeutic drug. The plasma was separated by
centrifugation and stored at -40°C until assayed. Plasma
CgA was measured by radioimmunoassay using '25I-labelled
CgA and rabbit antisera to purified CgA (O'Connor and
Bernstein, 1984; O'Connor et al., 1989). Separation of free
from bound CgA was accomplished by using a second
antibody (goat anti-rabbit gamma-globulin). The assay lower
limit of sensitivity is 2.0 ng ml-' at 90% B/Bo, with an intra-
assay variation of <9.1% and interassay variation of
< 16.7% (O'Connor et al., 1989).
Measurements ofurinary S-HIAA and creatinine
On the day of chemotherapy, urine samples were collected
for 24 h, starting with the infusion of the main
chemotherapeutic agent (time zero). Five consecutive, 2 h
samples, were obtained (0-2, 2-4, 4-6, 6-8, 8-10), fol-
lowed by a 14 h sample to complete the 24 h collection
period. Urine samples were diluted 1:100 with 0.1 M per-
chloric acid, mixed and centrifuged to eliminate any
precipitate. 5-HIAA was quantitated employing a high-
performance liquid chromatography (HPLC) procedure with
electrochemical detection (Cubeddu et al., 1990). The HPLC
system was composed of a PM-30A dual piston pump, a
Biophase 5 micron octadecylsilane (C18) reverse phase column
(25 cm x 4mm), and LC4B controller and a thin-layer
detection cell with dual glassy carbon electrodes
(Bioanalytical Systems, West Lafayette, IN, USA). The
detector potential was maintained at 550 mV vs a silver/silver
chloride reference electrode. A 30 pl aliquot of the acidified,
diluted urine was injected (loop injection) into the injection
port. The mobile phase consisted of 0.1 M citric acid, 0.05 M
disodium hydrogen phosphate, 1 mM disodium EDTA and
17% (v/v) methanol (pH 4.5). All separations were performed
isocratically at a flow rate of 1.3 1 min-'. The sensitivity of
the system was sufficient to detect 45 pg of 5-HIAA. The
quantity of 5-HIAA present in each urine sample was deter-
mined from a standard calibration curve. The urinary con-
centration of 5-HIAA was corrected for that of creatinine.
Urinary creatinine was measured by a commercially available
colorimetric direct creatinine (Bioanalytics Laboratories Inc.,
Palm City, FL, USA).
Statistical Assessment
All results are expressed as the mean value ± s.e.m. ANOVA
and Duncan's multiple range test were employed to compare
differences between groups. Paired t-test was used to make
one time comparison when baseline and treatment values
Table I Patient characteristics
Dacarbazine Nitrogen mustard Cyclophosphamide
(n=7) (n= 5) (n=8)
Age (years) 46 7 24 2 55 4
Sex (M/F) 1/6 2/3 2/6
Weight (kg) 66 ± 5 63 7 69 2
Type of tumour
Melanoma 3 - -
Lymphoma 1 5 2
Leiomyosarcoma 1 - -
Chondrosarcoma 1
Haemangiopericytoma I
Lung carcinoma - - 1
Breast carcinoma - - 5
Associated chemotherapeutic drugs
Alone 3 1 0
Actinomycin I -
Doxorubicin 1
Cyclophosphamide 1
Vin + proca + pred - 4
Doxo + vin + pred - - I
Doxo + vin + bleo - - 1
Doxo + vin - - I
Doxo + 5-FU - - 1
Novan + 5-FU - - 1
Methotrexate + 5-FU - - 3
Median time to the onset of emesis (h) 2.3 2.8 5.3
Age and weights are shown as means± s.e.m. Doxo, doxorubicin; vin, vincristine; proca,
procarbazine; pred, prednisone; novan, novanthrone; bleo, bleomycin; 5-FU, 5-fluorouracil.were obtained in the same subject. Repeated measures
ANOVA was used to evaluate multiple time points in the
same subject. Correlations were evaluated by linear least
squares regression analysis. A P-value below 0.05 was con-
sidered to indicate statistical significance.
Results
Pattern ofemesis and changes in plasma CgA levels and in
urinary excretion of5-HIAA after dacarbazine-based
chemotherapies
The effects of dacarbazine-based chemotherapies on plasma
CgA levels of urinary 5-HIAA excretion were studied in
seven patients with malignancies (Table I). Dacarbazine was
given as the sole agent in three subjects, and was associated
with other chemotherapeutic agents in four subjects (Table
I). The average dose ofdacarbazine was 193 ± 34mgm-2. In
six of the seven patients, dacarbazine-based chemotherapies
increased plasma CgA levels. Significant increases in plasma
CgA were already present at 3 h (47% increase above
baseline), and maximal increases (96% ± 21% increase above
baseline levels; P<0.001) were observed 5 h after initiation
of the dacarbazine infusion (Figure 1). CgA levels 24 h after
chemotherapy were not different from those at baseline
(Figure 1).
Similarly to CgA, the urinary excretion of 5-HIAA in-
creased significantly after dacarbazine-based chemotherapies
(Figure 1). Baseline 2 h excretion rate of 5-HIAA was
177 ± 30ftg and increased to 299 ± 68 tg (P<0.01) on the
urine sample collected from 4 to 6 h after chemotherapy
(Figure 1). In these patients, a total of 0.46 ± 0.2 mg of
5-HIAA were excreted above baseline levels, from 2 to 10 h
after dacarbazine administration. The time course for the
changes in 5-HIAA overlapped that of the changes in plasma
CgA. Highest CgA levels were obtained between 5 and 7 h
after dacarbazine, and the peak urinary excretion rates for
5-HIAA also occurred between 4 and 8 h after dacarbazine
(Figure 1).
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Figure 1 Pattern of emesis and increases in plasma CgA and
urinary 5-HIAA after dacarbazine-based chemotherapies in
cancer patients. Dacarbazine was infused for I h (black rectangle)
followed by the associated chemotherapeutic drugs (Table I).
Ordinates: left, plasma CgA concentration in ngml-l (0); right,
urinary excretion of 5-HIAA in pg 2 h-' (l). The 24 h depicted
value for 5-HIAA excretion represents the corrected 2 h excretion
for the 14 h urine collection period starting at hour 10 and
terminating at hour 24. Abscissa, time in hours. Zero time
represents the time of initiation of the dacarbazine infusion.
Vertical lines represent single episodes of emesis (incidence of
emesis for all patients).
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When present, emesis started approximately 2.5 h (mean:
2.5 ± 0.4 h; median: 2.3 h) after the initiation of the dacar-
bazine infusion (Table I). The pattern of emesis observed is
shown in Figure 1. Most of the emesis occurred between 2
and 5 h after the initiation of the dacarbazine infusion, the
time at which there were increases in plasma CgA and in
urinary 5-HIAA. After 5 h, only occasional episodes of
vomiting were recorded and both plasma CgA and urinary
5-HIAA showed a gradual return to baseline levels.
Pattern ofemesis and changes inplasma CgA levels and in
urinary excretion of5-HIAA after nitrogen mustard-based
chemotherapies
The effects ofnitrogen mustard on plasma CgA levels and on
the urinary excretion of 5-HIAA were studied in five patients
with malignancies (Figure 2). One patient received nitrogen
mustard alone, and in the other four subjects, the nitrogen
mustard was associated with vincristine (1-2 mg m2), pro-
carbazine (90-200 mg m-2) and prednisone (40-100 mg m
-2) (Table I). The average dose of nitrogen mustard was
4.9 ± 0.4 mg m-2. In all patients studied, nitrogen mustard-
based regimens were associated with increases in the plasma
CgA concentrations which peaked at 5 h (166 ± 7% increase
above baseline levels) (P<0.001). Significant increases were
already present at 3 h (96% ± 29% increase above baseline).
CgA levels 24 h after chemotherapy were not different from
baseline levels. The smallest percentage of increase in CgA
levels was observed in the patient receiving nitrogen mustard
alone (43% above baseline); whereas in the other four
patients, the percentage of increase above baseline levels
ranged from 116% to 250%.
To rule out the possible role of diurnal variations in CgA,
two CgA levels were drawn the day before the chemotherapy,
one in the morning (18.8 ± 2.4ng ml-) and the second, 5 h
later (19.8 ± 3.4 ngml-'). These levels were not different
from those at baseline on the day of chemotherapy
(15.8 ± 3.6 ngml-'), but highly different from those obtained
5 h after nitrogen mustard (47.2 ± 8 ngml-').
Similarly to CgA, the urinary excretion of 5-HIAA in-
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Figure 2 Pattern of emesis and increases in plasma CgA and in
urinary 5-HIAA after nitrogen mustard-based chemotherapies in
cancer patients. Nitrogen mustard was infused for 1 h (black
rectangle) followed by the associated chemotherapeutic drugs
(Table I). Ordinates: left, plasma CgA concentration in ngml '
(0); right, urinary excretion of 5-HIAA in 1sg 2 h- (l). The
24 h depicted value for 5-HIAA excretion represents the corrected
2 h excretion for the 14 h urine collection period starting at hour
10 and terminating at hour 24. Abscissa, time in hours. Zero time
represents the time of initiation of the nitrogen mustard infusion.
Vertical lines represent single episodes of emesis (incidence of
emesis for all patients).
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creased significantly after nitrogen mustard-based
chemotherapies (Figure 2). At baseline, the 2 h excretion rate
of 5-HIAA (0-2 h) was 284 ± 65 mg and increased to
562 ±170mg (P<0.01) between 4 and 6h after the
chemotherapy. In these pateints, a total of 0.91 ± 0.41 mg of
5-HIAA were excreted above baseline excretion, from 2 to
10 h after nitrogen mustard administration. The time course
of the changes in 5-HIAA paralleled that of plasma CgA.
Highest CgA levels were obtained between 3 and 7 h after
nitrogen mustard. Greater urinary excretion rates for 5-
HIAA also occurred between 2 and 8 h after the
chemotherapeutic drug (Figure 2).
When present, emesis started approximately 3 h
(mean ± s.e.m.: 3.8 ± 1.4 h; median: 2.8 h) after nitrogen
mustard administration. One subject did not vomit and two
subjects experienced more than five emetic episodes in 24 h.
The pattern of emesis in the subjects experiencing vomiting is
shown in Figure 2. Most intense emesis was experienced
between 2 and 4 h after initiating the nitrogen mustard
infusion. The period of intense emesis was associated with
sharp rises in the plasma levels of CgA and in the urinary
excretion of 5-HIAA (Figure 3).
Pattern ofemesis and changes in plasma CgA levels and in
urinary excretion of5-HIAA after cyclophosphamide-based
chemotherapies
The effects of cyclophosphamide on plasma CgA and on
urinary 5-HIAA excretion were studied in eight patients with
malignancies (Figure 4). The average dose of cyclophos-
phamide was 613 ± 99 mg m-2. Cyclophosphamide was given
in association with other chemotherapeutic drugs (Table 1).
Cyclophosphamide-based chemotherapies were not associated
with increases in the plasma CgA concentrations, in the 7 h
period following the administration of cyclophosphamide
(Figure 4). Plasma CgA at baseline and at 7 h after cyc-
lophosphamide averaged 26.4 ± 4.2 and 22.8 ± 6 ng ml-'
respectively (P>0.1). Similarly to CgA, the urinary excretion
of 5-HIAA failed to increase significantly after
cyclophosphamide-based chemotherapies. At baseline, the 2 h
excretion rate of 5-HIAA (0-2 h) was 192 ± 43 jig, and from
6 to 8 h and from 8 to 10 h after cyclophosphamide averaged
210 ± 37 jLg and 183 ± 37 jLg respectively (P<0.1) (Figure
4).
When present, emesis started approximately 5 h
(mean ± s.e.m.: 6 ± 1 h; median 5.3 h) after cyclophos-
phamide administration. Vomiting was present in half of the
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Figure 3 Pattern of emesis and increases in plasma CgA and in
urinary 5-HIAA after cyclophosphamide-based chemotherapies in
cancer patients. Cyclophosphamide was infused for 1 h (black
rectangle) followed by the associated chemotherapeutic drugs
(Table I). Ordinates: left, plasma CgA concentration in ngml'
(0); right, urinary excretion of 5-HIAA in fig 2 h-' (0). The
24 h depicted value for 5-HIAA excretion represents the corrected
2 h excretion for the 14 h urine collection period starting at hour
10 and terminating at hour 24. Abscissa, time in hours. Zero time
represents the time of initiation of the cyclophosphamide
infusion. Vertical lines represent single episodes of emesis
(incidence of emesis for all patients).
patients, since four subjects did not vomit. The pattern of
emesis in the patients who vomited is shown in Figure 4.
Most vomiting occurred between 5 and 11 h after initiation
of the cyclophosphamide infusion, with sporadic vomiting
thereafter. Compared with dacarbazine and nitrogen mus-
tard, when most of the vomiting occurred in a period of 2 to
3 h, vomiting associated with cyclophosphamide was spread
out over a period of 7 to 9 h (compare Figures 1, 3 and 4).
As shown in Figure 4, no increases in plasma CgA and in
urinary 5-HIAA were observed up to 7 and 10 h respectively,
after cyclophosphamide administration.
Relationship between the changes in plasma CgA and in
urinary S-HIAA
A highly significant (P = 0.0009) positive correlation
(r = 0.68) was found between the increases in plasma CgA
levels and the increases in the urinary excretion of 5-HIAA
after all chemotherapy treatments (Figure 5). When the cyc-
lophosphamide data were excluded from the correlation
analysis, a positive (r = 0.56), significant (P= 0.03) correla-
tion was still obtained for the increases in plasma CgA and
in urinary 5-HIAA.
Discussion
CgA is a 50 kDa acidic protein located in neurotransmitter
and hormone-containing secretory vesicles (O'Connor et al.,
1984; Winkler and Fischer-Colbrie, 1992). CgA may be a
prohormone precursor which is proteolitically processed
(Parmer et al., 1993a) into bioactive peptides which modulate
neuroendocrine secretion and may also play a central role in
the trafficking of proteins to secretory vesicle biogenesis
(Parmer et al., 1993b). The co-release of large storage granule
proteins (i.e. CgA, dopamine ,B-hydroxylase) with amine hor-
mones and neurotransmitters is the basis of the concept of
exocytosis (O'Connor and Bernstein, 1984; Takiyyuddin et
al., 1990). CgA is present in very high concentrations in the
gastrointestinal tract (O'Connor et al., 1983; Facer et al.,
1985; Varndell et al., 1985) and immunohistochemical studies
have demonstrated that enterochromaffin cells are an impor-
tant source of this protein (Cetin and Grube, 1991; Bargsten
and Grube, 1992). In these cells, CgA is stored along with
serotonin in the core of the secretory vesicles (Bargsten and
Grube, 1992).
In this work, dacarbazine- and nitrogen mustard-based
chemotherapies were associated with increases in the plasma
levels of CgA. These findings are in agreement with recent
observations, that in patients with cancer, plasma CgA con-
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Figure 4 Relationships between the increases in plasma CgA
concentration and in the urinary excretion of 5-HIAA. The
percentage increase above baseline values was calculated for the
peak increases in plasma CgA (ordinate) and in urinary 5-HIAA
excretion (abscissa) for dacarbazine- (0), nitrogen mustard- (0)
and cyclophosphamide (-)-treated patients.
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centrations are markedly elevated following treatment with
cisplatin (Cubeddu et al., 1994a). For dacarbazine, nitrogen
mustard, as well as for cisplatin (Cubeddu et al., 1994a), the
increases in plasma CgA were paralleled by increases in the
urinary excretion of 5-HIAA. Since the urinary output of
5-HIAA appears to be a reliable indicator of gastrointestinal
(enterochromaffin) serotonin release and turnover (Bertaccini,
1960; Bertaccini and Chieppa, 1960; Cubeddu, 1992), the
parallel time courses for the changes in CgA and in 5-HIAA,
and the significant and positive correlation observed between
plasma CgA and urinary 5-HIAA, suggest that both subs-
tances may have a common origin; possibly the enteroch-
romaffin cells. However, since CgA has a widespread dist-
ribution, we cannot rule out that plasma CgA could also
derive from other cell sources.
Recent evidence indicates that the nausea and emesis
induced by chemotherapeutic drugs is mediated by serotonin,
acting upon 5-HT3 receptors (Costall et al., 1986; Miner and
Sanger, 1986; Cubeddu et al., 1990; Cubeddu and Hoffman,
1993, 1994; Andrews, 1994). The site from which the
serotonin is released is still under debate. Clinical studies
indicate that neither cisplatin nor cyclophosphamide induces
the release of serotonin from platelets (Cubeddu et al., 1990;
Cubeddu, 1992). Therefore, serotonin could be released from
the gastrointestinal tract (enterochromaffin cells and/or
enteric serotonin neurons) and/or from central serotonergic
neurons involved in the control ofemesis, such as the nucleus
tractus solitarius, the site where most vagal afferent fibres
synapse (Hawthorn et al., 1988; Andrews, 1994). Serotonin
from the gastrointestinal tract would stimulate 5-HT3 recep-
tors located in vagal afferents, inducing marked increases in
visceral afferent inputs to the chemoreceptor trigger zone,
leading to nausea and emesis (Hawthorn et al., 1988; And-
rews, 1994). In guinea pigs and dogs, cisplatin releases
serotonin from enterochromaffin cells (Schw6rer et al., 1991;
Fukui et al., 1993). Results from this and other studies
(Cubeddu et al., 1990, 1992, 1994; Cubeddu, 1992; Cubeddu
and Hoffmann, 1993, 1994) suggest that strongly emetogenic
drugs release serotonin from enterochromaffin cells, and that
this release is reflected by increases in urinary 5-HIAA and in
plasma CgA. Because only a very small proportion of gast-
rointestinal serotonin is located in enteric neurons (compared
with enterochromaffin cell serotonin), any contribution of
neuronal serotonin to chemotherapy-induced emesis would
be obscured by the large release from enterochromaffin
cells.
It is important to emphasise that the increases in plasma
CgA and in urinary 5-HIAA associated with dacarbazine and
nitrogen mustard occured in parallel with the development of
intense vomiting, and that the levels of both substances
declined toward baseline levels as soon as emesis terminated.
However, cyclophosphamide-based chemotherapy regimens
were not accompanied by increases in the urinary excretion
of 5-HIAA (Cubeddu et al., 1992; present study) or in the
levels of plasma CgA (present study); suggesting that cyc-
lophosphamide does not induce serotonin release from
enterochromaffin cells. Nevertheless serotonin seems to be
involved in cyclophosphamide-induced emesis, since 5-HT3
antagonists are effective against cyclophosphamide-induced
emesis (Cubeddu et al., 1994b). Therefore, cyclophosphamide
at doses of 500 mg m2, may release serotonin from enteric
neurons and/or from the CNS. Studies in ferrets indicate that
cyclophosphamide has little effect on gastric and ileal mucosa
serotonin levels, but greatly affects serotonin levels in the
chemoreceptor trigger zone (Endo et al., 1992).
In order to make a valid comparison between dacarbazine,
nitrogen mustard and cyclophosphamide, a similar
antiemetic, metoclopramide, was employed in all patients. In
previous studies we demonstrated that the antiemetics metoc-
lopramide, dexamethasone and ondansetron did not alter the
magnitude of the increases in 5-HIAA and in plasma CgA
associated to cisplatin treatment (Cubeddu et al., 1990;
Cubeddu and Hoffmann, 1993, 1994). These results suggest
that the above-mentioned antiemetics do not interfere with
the release of serotonin induced by cisplatin. More impor-
tantly, the results indicate that the increases in CgA and in
5-HIAA were not the consequence of the act of vomiting;
since similar increases in plasma CgA and in urinary 5-HIAA
were observed in patients who vomited and in those who did
not vomit (Cubeddu et al., 1990; Cubeddu and Hoffmann,
1992, 1994). This is further supported by the observation that
vomiting induced by cyclophosphamide is not associated with
increases in plasma CgA or in urinary 5-HIAA (present
study). Ifvomiting were the cause ofthe elevations ofplasma
CgA and urinary 5-HIAA, cyclophosphamide treatment
would have been associated with increases in the levels of
both substances.
In summary, our findings indicate that in cancer patients
treated either with dacarbazine or nitrogen mustard, plasma
CgA is an indicator of serotonin release from enteroch-
romaffin cells. Since serotonin released triggers emesis,
Plasma CgA could also be used as marker of emesis for both
drugs. The parallel increases in plasma CgA and in urinary
5-HIAA suggest that exocytosis is the mechanism by which
serotonin is released. At the doses employed in this study
cyclophosphamide-induced emesis seems not to be mediated
by the release of serotonin from enterochromaffin cells, since
no increases in plasma CgA and in urinary 5-HIAA were
observed.
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